1 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia
with macrovascular and microvascular complications
of type 2 diabetes (UKPDS 35): prospective
observational study. BMJ 2000; 321: 405–412.
2 UKPDS. Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment
and risk of complications in patients with type 2
diabetes (UKPDS 33). UK Prospective Diabetes Study
Group. Lancet 1998; 352: 837–853.
3 Bradley C, Todd C, Gorton T, Symonds E, Martin A,
Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on
quality of life: the ADDQoL. Qual Life Res 1999; 8: 79–91.
4 Bradley C, Speight J. Patient perceptions of diabetes
and diabetes therapy: assessing quality of life. Diabetes
Metab Res Rev 2002; 18(Suppl. 3): S64–S69.
5 Wee HL, Tan CE, Goh SY, Li SC. Usefulness of the
Audit of Diabetes-Dependent Quality-of-Life (ADDQoL)
Questionnaire in patients with diabetes in a multi-ethnic
Asian country. Pharmacoeconomics 2006; 24: 673–682.
6 Nathan DM, Buse JB, Davidson MB et al. Management
of hyperglycaemia in type 2 diabetes: a consensus algorithm
for the initiation and adjustment of therapy:
a consensus statement from the American Diabetes
Association and the European Association for the
Study of Diabetes. Diabetologia 2006; 49: 1711–1721.
7 Polonsky WH, Fisher L, Guzman S, Villa-Caballero L,
Edelman SV. Psychological insulin resistance in
patients with type 2 diabetes: the scope of the problem.
Diabetes Care 2005; 28: 2543–2545.
8 Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P.
Delayed initiation of subcutaneous insulin therapy after
failure of oral glucose-lowering agents in patients with
type 2 diabetes: a population-based analysis in the UK.
Diabet Med 2007; 24: 1412–1418.
9 Yki-Jarvinen H, Juurinen L, Alvarsson M et al. INITIATE
(INITiate Insulin by Aggressive Titration and Education).
A randomized study to compare initiation of
insulin combination therapy in type 2 diabetic patients
individually and in groups. Diabetes Care 2007; 30:
1364–1369.
10 Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic
management of type I and type II diabetes.
Diabetologia 2002; 45: 937–948.
11 Morris AD. Addressing dosing frequency in diabetes:
a simple approach to improving adherence to therapy
and clinical outcomes. Diabetes Educ 2003; 29: 440–
446, 448, 450–443.
12 Polonsky WH. Emotional and quality-of-life aspects of
diabetes management. Curr Diab Rep 2002; 2: 153–159.
13 Speight J, Bradley C. The Dose Adjustment For Normal
Eating (DAFNE) Trail: what makes people with type 1
diabetes agree/decline to participate? Diabet Med 2001;
18: 129.
14 Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed
health outcome measures for diabetes: a structured
review. Diabet Med 2002; 19: 1–11.
15 Bradley C. The Diabetes Treatment Satisfaction Questionnaire:
DTSQ. In: Bradley C, ed. Handbook of Psychology
and Diabetes: A Guide to Psychological
Measurement in Diabetes Research and Practice.
Chur, Switzerland: Harwood Academic Publishers, 1994;
111–133.
16 Bradley C, Lewis KS. Measures of psychological wellbeing
and treatment satisfaction developed from the
responses of people with tablet-treated diabetes. Diabet
Med 1990; 7: 445–451.
17 Anderson RT, Skovlund SE, Marrero D et al. Development
and validation of the Insulin Treatment Satisfaction
Questionnaire. Clin Ther 2004; 26: 565–578.
18 Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development
of a type 2 diabetes symptom checklist: a
measure of symptom severity. Diabet Med 1994; 11:
253–261.
19 Bradley C. The Well-Being Questionnaire. In: Bradley
C, ed. Handbook of Psychology and Diabetes: A Guide
to Psychological Measurement in Diabetes Research
and Practice. Chur, Switzerland: Harwood Academic
Publishers, 1994; 89–109.
20 Bradley C, Gamsu DS. Guidelines for encouraging psychological
well-being: report of a Working Group of the
World Health Organization Regional Office for Europe
and International Diabetes Federation European Region
St Vincent Declaration Action Programme for Diabetes.
Diabet Med 1994; 11: 510–516.
21 Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley
C, Ward JD. Randomized trial comparing continuous
subcutaneous insulin infusion and conventional insulin
therapy in type II diabetic patients poorly
controlled with sulfonylureas. Diabetes Care 1991; 14:
738–744.
22 Taylor R, Foster B, Kyne-Grzebalski D, Vanderpump M.
Insulin regimens for the non-insulin dependent: impact
on diurnal metabolic state and quality of life. Diabet
Med 1994; 11: 551–557.
23 Wilson M, Moore MP, Lunt H. Treatment satisfaction
after commencement of insulin in type 2 diabetes. Diabetes
Res Clin Pract 2004; 66: 263–267.
24 Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska
D, Schabmann A, Bradley C. Dealing with ceiling baseline
treatment satisfaction level in patients with diabetes
under flexible, functional insulin treatment:
assessment of improvements in treatment satisfaction
with a new insulin analogue. Qual Life Res 2000; 9:
915–930.
25 Bradley C. Diabetes Treatment Satisfaction Questionnaire.
Change version for use alongside status version
provides appropriate solution where ceiling effects
occur. Diabetes Care 1999; 22: 530–532.
26 Bradley C, Plowright R, Stewart J, Valentine J, Witthaus
E. The Diabetes Treatment Satisfaction Questionnaire
change version (DTSQc) evaluated in insulin glargine
trials shows greater responsiveness to improvements
than the original DTSQ. Health Qual Life Outcomes
2007; 5: 57.
27 Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA,
Dempsey E. A randomized trial of adding insulin glargine
vs. avoidance of insulin in people with type 2 diabetes
on either no oral glucose-lowering agents or
submaximal doses of metformin and/or sulphonylureas.
The Canadian INSIGHT (Implementing New Strategies
with Insulin Glargine for Hyperglycaemia Treatment)
Study. Diabet Med 2006; 23: 736–742. 28 Houlden R, Ross S, Harris S, Yale JF, Sauriol L,
Gerstein HC. Treatment satisfaction and quality of
life using an early insulinization strategy with insulin
glargine compared to an adjusted oral therapy in
the management of type 2 diabetes: the Canadian
INSIGHT Study. Diabetes Res Clin Pract 2007; 78:
254–258.
29 Mitchell J, Wolffsohn JS, Woodcock A et al.
þPsychometric evaluation of the MacDQoL individualised
measure of the impact of macular degeneration
on quality of life. Health Qual Life Outcomes 2005;
3: 25.
30 Woodcock A, Bradley C, Plowright R, Ffytche T,
Kennedy-Martin T, Hirsch A. The influence of diabetic
retinopathy on quality of life: interviews to guide the
design of a condition-specific, individualised questionnaire:
the RetDQoL. Patient Educ Couns 2004; 53:
365–383.
31 Shen W, Kotsanos JG, Huster WJ, Mathias SD,
Andrejasich CM, Patrick DL. Development and validation
of the Diabetes Quality of Life Clinical Trial Questionnaire.
Med Care 1999; 37: AS45–AS66.
32 Hayes R, Bowman L. Reliability and validity of
the Treatment Flexibility Scale. Qual Life Res 2003;
12: 863.
33 Riazi A, Ishii H, Barendse S, Bradley C. Well-Being
Questionnaire (W-BQ): translation and psychometric
development of a short form (W-BQ12) in Japanese.
Proc Br Psychol Soc 1999; 7(Suppl. 1): 34A.
34 Riazi A, Bradley C, Barendse S, Ishii H. Development of
the Well-Being Questionnaire short-form in Japanese:
the W-BQ12. Health Qual Life Outcomes 2006; 4: 40.
35 Witthaus E, Stewart J, Bradley C. Treatment satisfaction
and psychological well-being with insulin glargine
compared with NPH in patients with type 1 diabetes.
Diabet Med 2001; 18: 619–625.
36 Pouwer F, Snoek FJ, van der Ploeg HM, Ader HJ, Heine
RJ. The Well-Being Questionnaire: evidence for a threefactor
structure with 12 items (W-BQ12). Psychol Med
2000; 30: 455–462.
37 Mitchell J, Bradley C. Psychometric evaluation of the
12-item Well-Being Questionnaire for use with people
with macular disease. Qual Life Res 2001; 10: 465–473.
38 McMillan CV, Bradley C, Gibney J, Russell-Jones DL,
Sonksen PH. Psychometric properties of two measures
of psychological well-being in adult growth hormone
deficiency. Health Qual Life Outcomes 2006; 4: 16.
39 Weisbord SD, Fried LF, Arnold RM et al. Development
of a symptom assessment instrument for chronic hemodialysis
patients: the Dialysis Symptom Index. J Pain
Symptom Manage 2004; 27: 226–240.
40 Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone:
health-related quality-of-life impact in type 2
diabetes. Diabetes Care 2007; 30: 795–800.
41 Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH,
Brodows RG. Exenatide versus insulin glargine in
patients with suboptimally controlled type 2 diabetes:
a randomized trial. Ann Intern Med 2005; 143:
559–569.
42 Secnik Boye K, Matza LS, Oglesby A et al. Patientreported
outcomes in a trial of exenatide and insulin
glargine for the treatment of type 2 diabetes. Health
Qual Life Outcomes 2006; 4: 80.
43 Bradley C. Importance of differentiating health status
from quality of life. Lancet 2001; 357: 7–8.
44 Mitchell J, Bradley C. Measuring quality of life in macular
disease: what use are utilities? Proc Vis 2005; Int
Congr Ser 2005; 1282: 654–658.
45 Ware JE Jr, Sherbourne CD. The MOS 36-item shortform
health survey (SF-36). I. Conceptual framework
and item selection. Med Care 1992; 30: 473–483.
46 Woodcock AJ, Julious SA, Kinmonth AL, Campbell MJ.
Problems with the performance of the SF-36 among
people with type 2 diabetes in general practice. Qual
Life Res 2001; 10: 661–670.
47 Meneghini LF, Schwartz S, Rak ES, Harris A, Strange P.
Improved glycemic control with insulin glargine
(GLAR) vs pioglitazone (PIO) as add-on therapy in
patients with type 2 diabetes (T2D) uncontrolled on
sulfonylurea (SU) or metformin (MET) monotherapy.
Diabetes 2005; 54 (Suppl. 1) (Abstract 10-LB). Available
online at http://professional.diabetes.org/abstracts_displays.
aspx?TYP=1&CID=52535.
48 Fischer JS, McLaughlin T, Loza L, Beauchamp R,
Schwartz S, Kipnes M. The impact of insulin glargine
on clinical and humanistic outcomes in patients
uncontrolled on other insulin and oral agents: an
office-based naturalistic study. Curr Med Res Opin
2004; 20: 1703–1710.
49 Witthaus E, Stewart J, Bradley C. Improved psychological
outcomes after initiation of insulin treatment in
patients with type II diabetes. Diabetologia 2000; 43
(Suppl. 1): A205.
50 Rosenstock J, Sugimoto D, Strange P, Stewart JA,
Soltes-Rak E, Dailey G. Triple therapy in type 2
diabetes: insulin glargine or rosiglitazone added to
combination therapy of sulfonylurea plus metformin
in insulin-naive patients. Diabetes Care 2006; 29:
554–559.
51 Meneghini LF, Schwartz S, Strange P, Oster G. Healthrelated
quality of life and costs of receiving add-on
therapy with insulin glargine or pioglitazone in
patients with type 2 diabetes. Diabetologia 2006; 49
(Suppl. 1): 543 (Abstract 0894).
52 Vinik AI, Zhang Q. Health-related quality of life
(HRQOL) and early study termination in patients adding
insulin vs a thiazolidinedione to one or two oral
agents. Diabetes 2006; 55 (Suppl. 1): A137 (Abstract
576-P).
53 Massi Benedetti M, Humburg E, Dressler A, Ziemen M.
A one-year, randomised, multicentre trial comparing
insulin glargine with NPH insulin in combination withoral agents in patients with type 2 diabetes. Horm
Metab Res 2003; 35: 189–196.
54 Bretzel RG, Nuber U, Landgraf W et al. Once-daily
basal insulin glargine versus thrice-daily prandial insulin
lispro in people with type 2 diabetes on oral
hypoglycaemic agents (APOLLO): an open randomised
controlled trial. Lancet 2008; 371: 1073–1084.
55 DAFNE Study Group. Training in flexible, intensive insulin
management to enable dietary freedom in people with
type 1 diabetes: Dose Adjustment for Normal Eating
(DAFNE) randomised controlled trial. BMJ 2002; 325: 746.
56 Raskin P, Allen E, Hollander P et al. Initiating insulin
therapy in type 2 diabetes: a comparison of biphasic and
basal insulin analogs. Diabetes Care 2005; 28: 260–265.
57 Brod M, Cobden D, Lammert M, Bushnell D, Raskin P.
Examining correlates of treatment satisfaction for
injectable insulin in type 2 diabetes: lessons learned
from a clinical trial comparing biphasic and basal analogues.
Health Qual Life Outcomes 2007; 5: 8.
58 Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C,
Schweitzer MA, Yki-Jarvinen H. Comparison of basal
insulin added to oral agents versus twice-daily premixed
insulin as initial insulin therapy for type 2 diabetes.
Diabetes Care 2005; 28: 254–259.
59 Bradley C, El-Haschimi K. Treatment satisfaction in
patients with type 2 diabetes: basal insulin plus oral
agents versus twice-daily premixed insulin alone –
analyses by country. Diabet Med 2006; 23 (Suppl. 1):
361 (Abstract P1010).
60 Yoo BK, Triller DM, Yoo DJ. Exenatide: a new option
for the treatment of type 2 diabetes. Ann Pharmacother
2006; 40: 1777–1784.
61 Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert
M, McEwan P. Multivariate models of health-related
utility and the fear of hypoglycaemia in people with
diabetes. Curr Med Res Opin 2006; 22: 1523–1534.
62 Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G,
Butterfield J. Fear of hypoglycemia: quantification, validation,
and utilization. Diabetes Care 1987; 10: 617–621.
63 Irvine A, Cox D, Gonder-Frederick L. The Fear of Hypoglycaemia
Scale. In: Bradley C, ed. Handbook of
Psychology and Diabetes: A Guide to Psychological
Measurement in Diabetes Research and Practice. Chur,
Switzerland: Harwood Academic Publishers, 1994;
133–155.
64 de Luis DA, Aller R, Cuellar L et al. Effect on quality of
life with a new insulin injection device in elderly
patients with diabetes mellitus type 2. J Diabetes Complications
2004; 18: 216–219.
65 Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A
multicenter, randomized, open-label, comparative,
two-period crossover trial of preference, efficacy, and
safety profiles of a prefilled, disposable pen and conventional
vial/syringe for insulin injection in patients
with type 1 or 2 diabetes mellitus. Clin Ther 2003; 25:
2836–2848.
66 Rubin RR, Peyrot M. Quality of life, treatment satisfaction,
and treatment preference associated with use of
a pen device delivering a premixed 70/30 insulin
aspart suspension (aspart protamine suspension/soluble
aspart) versus alternative treatment strategies. Diabetes
Care 2004; 27: 2495–2497.
67 Stockl K, Ory C, Vanderplas A et al. An evaluation of
patient preference for an alternative insulin delivery
system compared to standard vial and syringe. Curr
Med Res Opin 2007; 23: 133–146.
68 Summers KH, Szeinbach SL, Lenox SM. Preference for
insulin delivery systems among current insulin users
and nonusers. Clin Ther 2004; 26: 1498–1505.
69 Jacobsen AM; DCCT Research Group. The Diabetes
Quality of Life Measure. In: Bradley C, ed. Handbook of
Psychology and Diabetes: A Guide to Psychological
Measurement in Diabetes Research and Practice. Chur,
Switzerland: Harwood Academic Publishers, 1994;
65–87.
70 Davis TM, Clifford RM, Davis WA. Effect of insulin
therapy on quality of life in type 2 diabetes mellitus:
the Fremantle Diabetes Study. Diabetes Res Clin Pract
2001; 52: 63–71.
71 UKPDS. Quality of life in type 2 diabetic patients is
affected by complications but not by intensive policies
to improve blood glucose or blood pressure control
(UKPDS 37). UK Prospective Diabetes Study Group.
Diabetes Care 1999; 22: 1125–1136.